Tag: Lexicon Pharmaceuticals

2015-highlights

10 Highlights of the Year 2015 for the Carcinoid and Neuroendocrine Tumor Community

January 5, 2016

As we begin a new year, the Carcinoid Cancer Foundation looks back on the highlights of 2015 and to a future that we hope will bring greater awareness of carcinoid and neuroendocrine cancers, earlier diagnosis for patients, new treatment options, and …

READ MORE
Big Apple NETs_0

December Luncheon with the Experts in New York City for the Carcinoid and Neuroendocrine Tumor Community

November 6, 2015

Carcinoid and neuroendocrine tumor (NET) patients have a unique opportunity to hear from three medical experts during Lunch with the Experts in New York City on Sunday, December 6, 2015. This special program was initiated and is sponsored by the Big Apple

READ MORE
Big Apple NETs_0

September Luncheon with the Experts in New York City — Carcinoid and Neuroendocrine Tumor Patients Are Invited!

August 16, 2015

Carcinoid and neuroendocrine tumor (NET) patients are invited to join three medical experts for Lunch with the Experts in New York City on Sunday, September 27, 2015 at 12:30 pm. This special program was initiated and is sponsored by the Big Apple NETs

READ MORE
Carcinoid Syndrome, Lexicon Pharmaceuticals, Telotristat Etiprate Clinical Trial

Lexicon’s Carcinoid Syndrome Treatment Meets Primary Endpoint in Phase III Clinical Trial

August 5, 2015

Lexicon Pharmaceuticals Inc. has announced that the pivotal phase III clinical trial, TELESTAR, of its oral drug candidate telotristat etiprate met the primary endpoint in treating cancer patients with carcinoid syndrome that is not adequately controlled…

READ MORE
Immunotherapy Researchers, June, Hu, Kunz

10 Highlights of the Year 2014 for the Carcinoid and Neuroendocrine Tumor Community

December 18, 2014

As the Carcinoid Cancer Foundation looks back on the year 2014, we reached out to physicians, patients, support group leaders, listserv managers, patient advocates, and business colleagues to see what they thought were among the highlights of the past…

READ MORE
Big Apple NYC_2

Luncheon with Carcinoid and Neuroendocrine Tumor Experts in New York City

November 13, 2014

The Big Apple Noids support group invites you to join fellow carcinoid and neuroendocrine tumor (NET) patients and three medical experts for Lunch with the Experts on Sunday, December 14, 2014 at 12:30 pm in a private dining room at Dorrian’s restaurant

READ MORE
Lexicon Telestar_2

Lexicon Pharmaceuticals, Inc. Continues Recruiting for Phase 3 Studies in Carcinoid Syndrome

August 20, 2014

Many patients face the challenge of controlling carcinoid syndrome which can persist even while being treated with somatostatin analog (SSA) therapy. For patients on SSA therapy who continue to experience conditions such as diarrhea, frequent bowel…

READ MORE
Telotristat Etiprate Clinical Trial

Discover Something New in Carcinoid Syndrome

November 11, 2013

For patients who suffer from carcinoid syndrome – with symptoms such as diarrhea, frequent bowel movements, abdominal pain, and flushing – that is not adequately controlled by their current somatostatin analog therapy, there is an opportunity to participate…

READ MORE
Pablo Lapuerta, MD

Lexicon Pharmaceuticals Begins Phase 3 Clinical Trial of Telotristat Etiprate in Patients with Carcinoid Syndrome

December 4, 2012

Patients with metastatic carcinoid syndrome will have the opportunity to participate in a new Phase 3 clinical trial of Lexicon Pharmaceutical’s telotristat etiprate (LX1032), an oral drug candidate designed to treat carcinoid syndrome by reducing…

READ MORE
Lexicon Headquarters

Lexicon Pharmaceuticals Granted Orphan Drug Designation by FDA for Carcinoid Syndrome Treatment

April 2, 2012

Lexicon Pharmaceuticals, Inc. has been granted Orphan Drug Designation for telotristat etiprate (LX1032) by the U.S. Food and Drug Administration (FDA).  LX1032 is used to treat carcinoid syndrome, a chronic condition caused by neuroendocrine tumors,…

READ MORE